Exploring the “chemo” in chemoimmunotherapy for triple-negative breast cancer
Cancer Cell · 2025
DOI: 10.1016/j.ccell.2025.02.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025. Verfasst von Ting Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
In this issue of Cancer Cell, Zhang et al. use single-cell RNA sequencing to compare immune cell dynamics in triple-negative breast cancers treated with the PD-L1 inhibitor atezolizumab plus paclitaxel or nab-paclitaxel. They identify distinct T cell activation patterns and highlight mast cells' role in immune activation exclusively in the nab-paclitaxel combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Boston, MA 02115, USA. Electronic address: lellisen@mgh.harvard.edu.
Zitieren
APA
Liu, T., & Ellisen, L. W. (2025). Exploring the “chemo” in chemoimmunotherapy for triple-negative breast cancer. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.02.016
Vancouver
Liu T, Ellisen LW. Exploring the “chemo” in chemoimmunotherapy for triple-negative breast cancer. Cancer Cell. 2025. doi:10.1016/j.ccell.2025.02.016
BibTeX
@article{Liu2025,
author = {Liu, Ting and Ellisen, Leif W},
title = {Exploring the “chemo” in chemoimmunotherapy for triple-negative breast cancer},
journal = {Cancer Cell},
year = {2025},
doi = {10.1016/j.ccell.2025.02.016}
}
EUVIMED